“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Search
Thelaziosis dog eyeworms
Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
We’re All In
Watch our video to learn about our approach to innovation and partnerships
Lung Diseases
Lung Diseases
Sustainable Development
Sustainable Development
Company Culture
Company Culture
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Living Independence
Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Bees and biodiversity
At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
university-of-medical-excellence-harvard
A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Diabetes
Diabetes
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Scouting for digital innovation
Get to know our digital scouts who look-out for emerging technologies and trends that could benefit our patients.
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Patient centricity and site centricity in clinical trials
We are partnering with patients, caregivers and trial site staff to design and conduct our clinical trials, to provide a better experience for all.
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.